By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases will spend $9.3 million in Fiscal Year 2013 to fund research and development of new diagnostic and therapeutic countermeasures for use in biodefense efforts against dangerous pathogens and toxins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.